A Randomized Phase II/III Trial of Prophylactic Cranial Irradiation with or without Hippocampal Avoidance for Small Cell Lung Cancer
Principal Investigator
Vinai Gondi, MD
Status
Closed to Accrual
Date Opened To Accrual
December 07 2015
Date Closed to Accrual
June 21 2022
Disease Site
Symptom Management [CC]
Other
Phase
II/III
Developmental Therapeutics
No
Primary Objective
To determine whether the 12-month intracranial relapse rate following HA-PCI is non-inferior compared to the rate following PCI for patients with SCLC
To determine whether HA-PCI reduces the likelihood of 6-month deterioration from baseline in HVLT-R delayed recall compared to the PCI for patients with SCLC
Patient Population
Histologic proof or unequivocal cytologic proof (fine needle aspiration, biopsy or two positive sputa) of SCLC within 250 days prior to Step 1 registration; Zubrod performance status 0-2; Patients who are primary English or French speakers are eligible.
Target Accrual
392
Patient Study Webpage
There is no available patient study webpage available for this trial at this time.